共享表位对欧洲类风湿关节炎患者生物制剂疗效的影响
该研究基于瑞士和丹麦风湿病注册队列,纳入464例启动四种bDMARD治疗的RA患者并进行倾向评分1:1匹配,比较SE阳性与阴性患者的疗效。结果显示,各bDMARD组中SE状态与1年治疗留存率、低疾病活动度和缓解率均无显著关联。
要点
- SE阳性与阴性RA患者在接受abatacept、TNFi、rituximab或tocilizumab治疗时,1年治疗留存率无显著差异。
- 四种bDMARD的LDA和缓解率在SE阳性与阴性患者间均无显著差异。
- 敏感性分析结果与主分析一致,SE状态不影响bDMARD疗效。
核心结论
- 在主要为欧洲血统的RA患者中,SE状态与bDMARD疗效无显著关联。
研究设计与样本
- 嵌套队列研究,基于瑞士SCQM和丹麦DANBIO风湿病注册队列。
- 纳入启动bDMARD治疗且有DNA样本可定义SE的RA患者,分abatacept、TNFi、rituximab、tocilizumab四组。
- 采用倾向评分1:1匹配比较SE阳性与阴性患者,每组匹配464例。
主要发现
- 匹配人群中SE阴性占31%,一个SE等位基因占48%,两个等位基因占21%。
- 所有bDMARD组粗1年治疗留存率不受SE状态影响。
- Cox回归分析显示SE阳性vs阴性的HR:abatacept 0.99(95%CI 0.71-1.38),TNFi 1.01(0.66-1.54),rituximab 1.14(0.71-1.84),tocilizumab 1.48(0.92-2.40)。
- 四种bDMARD的LDA和缓解率均不受SE状态影响,敏感性分析结果相似。
临床怎么用
- 在本研究人群中,SE状态不应作为选择abatacept、TNFi、rituximab或tocilizumab的预测生物标志物。
局限性
- 研究主要纳入欧洲血统患者,结论外推至其他人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For rheumatoid arthritis (RA), the HLA-DRB1 'shared epitope' (SE) allele has been proposed as a predictive biomarker for the effectiveness of mainly abatacept and other biologic disease-modifying antirheumatic drugs (bDMARDs). OBJECTIVE: To explore the relative impact of SE positivity on the effectiveness of different bDMARDs in European patients with RA. METHODS: Nested cohort study in the Swiss (Swiss Clinical Quality Management) and Danish (DANBIO) rheumatology registries. Patients with RA who initiated bDMARD treatment and had available DNA samples to define SE were included. Four bDMARD groups were defined: abatacept, tumour necrosis factor inhibitors (TNFi), rituximab, tocilizumab. Patients were matched 1:1 using propensity scores and the effectiveness compared between patients being SE positive versus SE negative. For sensitivity, the number of SE alleles was included. Primary end point was treatment retention (crude by SE status, adjusted Cox regression analyses including relevant covariates). Secondary end points were low disease activity (LDA) and remission (1, 2 years). RESULTS: Of the 5248 treatment courses initially identified, 464 patients in each of the four bDMARD groups were matched (SE negative: 31%, one SE allele: 48%, two alleles: 21%). For all bDMARD groups, crude 1-year treatment retention was unaffected by SE status. Cox regression analyses showed non-significant HRs for SE-positive versus SE-negative patients: abatacept 0.99 (95% CI 0.71 to 1.38), TNFi 1.01 (0.66 to 1.54), rituximab 1.14 (0.71 to 1.84), tocilizumab 1.48 (0.92 to 2.40). LDA and remission rates were unaffected by SE status for all four bDMARDs. Sensitivity analyses showed similar results. CONCLUSION: In the current study, the SE was not associated with bDMARD effectiveness in patients with RA of mainly European ancestry.
引用
- Finckh A, Courvoisier DS, Aymon R, et al. Influence of the shared epitope on the effectiveness of biologic antirheumatic agents in European patients with rheumatoid arthritis. RMD Open. 2026. PMID: 42425718. doi:10.1136/rmdopen-2026-006788
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。